ClinicaliQ Trial Snapshot
- A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy — Active Not Recruiting • Phase II • NCT05548556.
- A study testing a new antibody drug to block myostatin in adults with facioscapulohumeral muscular dystrophy.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD). Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD) Interventions: Placebo, RO7204239 Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 51 participants